نتائج البحث - Peter D’Andrea

  • يعرض 1 - 5 نتائج من 5
تنقيح النتائج
  1. 1
    Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

    Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study حسب Kai-Michael Beeh, Stephanie Korn, Jutta Beier, Dalal Jadayel, Michelle Henley, Peter D’Andrea, Donald Banerji

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients

    Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients حسب Jadwiga A. Wedzicha, Ronald Dahl, Roland Buhl, Agnes Annette Schubert-Tennigkeit, Hungta Chen, Peter D’Andrea, Robert Fogel, Donald Banerji

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease

    Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease حسب James F. Donohue, Paul Jones, Christian Bartels, Jessica Marvel, Peter D’Andrea, Donald Banerji, David G. Morris, Francesco Patalano, Robert Fogel

    منشور في 2017
    احصل على النص الكامل
    Revisão
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

    A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study حسب Kenneth R. Chapman, Kai Michael Beeh, Jutta Beier, Eric Bateman, Anthony D’Urzo, Robert Nutbrown, Michelle Henley, Hungta Chen, Tim Overend, Peter D’Andrea

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

    Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma... حسب Huib A.M. Kerstjens, Jorge Máspero, Kenneth R. Chapman, Richard N. van Zyl-Smit, Motoi Hosoe, Ana-Maria Tanase, Catherine Lavecchia, Abhijit Pethe, Xu Shu, Peter D’Andrea

    منشور في 2020
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: